Shire PLC (LON:SHP)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank Of Canada in a research report issued on Friday, July 7th, Marketbeat.com reports.
A number of other research firms have also weighed in on SHP. J P Morgan Chase & Co reiterated an “overweight” rating and issued a GBX 6,000 ($77.72) target price on shares of Shire PLC in a research note on Monday, March 27th. Barclays PLC reiterated an “overweight” rating and issued a GBX 6,300 ($81.61) target price on shares of Shire PLC in a research note on Monday, July 3rd. Liberum Capital reiterated a “buy” rating and issued a GBX 5,500 ($71.24) target price on shares of Shire PLC in a research note on Monday, April 10th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research note on Wednesday, April 12th. Finally, Credit Suisse Group restated an “outperform” rating and set a GBX 5,400 ($69.95) price target on shares of Shire PLC in a research note on Wednesday, May 3rd. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of GBX 6,024 ($78.03).
Shares of Shire PLC (LON SHP) traded down 0.13% on Friday, reaching GBX 4169.50. 1,617,077 shares of the company’s stock were exchanged. Shire PLC has a one year low of GBX 4,025.00 and a one year high of GBX 5,377.00. The company’s 50 day moving average is GBX 4,526.50 and its 200-day moving average is GBX 4,615.89. The stock’s market cap is GBX 37.70 billion.
ILLEGAL ACTIVITY WARNING: “Shire PLC’s (SHP) “Outperform” Rating Reiterated at Royal Bank Of Canada” was reported by BBNS and is owned by of BBNS. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://baseballnewssource.com/markets/shire-plcs-shp-outperform-rating-reaffirmed-at-royal-bank-of-canada/1169419.html.
In related news, insider Dominic Blakemore bought 152 shares of the business’s stock in a transaction on Friday, June 30th. The shares were bought at an average price of GBX 4,255 ($55.12) per share, for a total transaction of £6,467.60 ($8,377.72).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.